

## **CERTIFICATE OF ANALYSIS**

Important Note:	Centrifuge before opening to ensure complete recovery of vial contents.		
Catalog #:	R86380	Lot #:	8E12521
Description:	Influenza A (A/New Caledonia) Influenza Virus, Type A (H1N1), Strain A/New Caledonia/2	0/99 IVR116	
Source:	Allantoic fluid of 10 day old embryonated eggs, inoculated v Strain: A/New Caledonia/20/99 IVR 116	vith Influenza A virus.	
Format:	Purified, Liquid		
Purification:	>90% pure (SDS-PAGE). Ultracentrifugation using 10-40%	6 sucrose gradient.	
Concentration:	1.0 mg/mL (BCA Method)		
Buffer:	0.05 M Tris-HCl, pH 8.0 containing 0.1 M Sodium Chloride	, 5 mM EDTA.	
Preservative:	0.09% Sodium Azide, 0.005% Thimerosal.		
Applications:	Serological studies of influenza A virus, Immunogen for ant Influenza A (Catalog #C86305M) in ELISA. Each laborator for use in its particular application. Other applications have not necessarily be excluded.	ry should determine an	optimum working titer
Storage:	Upon receipt, store at -20°C. Avoid multiple freeze/thaw cy	cles.	
Inactivation:	0.005% Thimerosal and beta propiolactone.		
Safety Note(s):	Refer to the appropriate Safety Data Sheet (SDS) for additio	nal information.	
References:	<ol> <li>The references listed below are for research purposes only:</li> <li>Long, B.R., et al., (2008), "Elevated Frequency of Gama Adults Vaccinated against Influenza Virus", <u>Clinical an</u></li> <li>Alarcon, JB., et al., (2007), "Preclinical Evaluation of M Delivery of Influenza Vaccines", <u>Clinical and Vaccine I</u></li> </ol>	d Vaccine Immunology ficroneedle Technology	<i>I</i> , <b>15</b> (1): 120-130. <i>y</i> for Intradermal

Brancagele

Quality Signature:

08 JUN 2021

## FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY